Investment Set To Rise, Non-COVID R&D To Normalize As Korean Pharma Looks Ahead To 2022

Last Year Marked By Solid R&D, Financing Progress

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.